How should Tasigna be taken in relation to meals?

Dosing follows strict fasting rules to prevent excessive exposure. Capsules are taken twice daily, at least two hours after any food, then a one-hour wait precedes the next meal. Capsules are swallowed whole with water; if swallowing is not feasible, each capsule can be opened and mixed with one teaspoon of applesauce and taken immediately. Grapefruit juice and grapefruit should be avoided because they may increase nilotinib levels. Adhering to the fasting window and avoiding interacting foods helps maintain predictable drug levels and reduce adverse effects.

What monitoring typically accompanies Tasigna therapy?

Regular monitoring includes complete blood counts to assess marrow response and tolerability; liver and pancreas function tests; electrolyte checks for potassium and magnesium; and ECGs to evaluate the QT interval. Clinicians additionally monitor cardiovascular risk and watch for signs of fluid retention, pancreatitis, or serious skin reactions. In paediatric patients, growth is followed at regular visits. Monitoring cadence and any dose adjustments are individualized according to response, tolerability, and concomitant medications that might interact with nilotinib.

How does nilotinib work against CML?

Nilotinib binds to the ATP-binding site of the BCR-ABL1 tyrosine kinase created by the Philadelphia chromosome translocation. This prevents phosphorylation events needed for proliferation and survival of CML cells, thereby reducing leukemic burden and allowing normal haematopoiesis to recover. Because the kinase is the key driver of disease biology, sustained inhibition can translate into cytogenetic and molecular responses when therapy is taken as directed and monitored appropriately.

What symptoms suggest chronic myeloid leukaemia?

CML may be asymptomatic at diagnosis, discovered through routine blood tests showing elevated white counts. When present, symptoms can include fatigue, night sweats, bone or limb pain, abdominal fullness from splenomegaly, recurrent infections, easy bruising or bleeding, and breathlessness related to anaemia. Such manifestations reflect overproduction of abnormal white blood cells and marrow dysfunction. Diagnosis integrates blood counts, bone-marrow/ cytogenetic testing, and molecular assays confirming BCR-ABL1. Targeted therapy such as nilotinib addresses this driver lesion to control disease activity.

Why is ECG monitoring important in CML patients treated with Tasigna?

Nilotinib can prolong the QT interval, a measure of cardiac repolarization. Prolongation may predispose to arrhythmias, especially in the presence of electrolyte abnormalities, pre-existing heart disease, or interacting medicines. The patient leaflet specifies ECG assessment before starting therapy and at intervals thereafter, with correction of low potassium or magnesium and consideration of cardiovascular risk. Monitoring supports safe dosing and early identification of individuals who may require adjustments or additional investigation.

What happens if a scheduled dose of Tasigna is missed?

If a dose is forgotten, the next dose is taken as scheduled without doubling, according to the leaflet’s guidance. Consistent timing of approximately twelve hours between dosessupports steady exposure. Because food substantially increases nilotinib absorption, maintaining the two-hour pre-dose fast and one-hour post-dose fast is emphasized at each administration. Any decisions regarding interruptions, re-starts, or discontinuation are made by the prescribing team based on response, tolerability, and monitoring results.

Spend $99, get free U.S. shipping*

Tariff now required on U.S. shipments. Learn more »

Tel: 1-866-456-3768 Fax: 1-866-544-8993

Home / Online Pharmacy / Tasigna

For visual reference only; actual product may vary

US Name:

Tasigna
Alternative Names:

Tasigna
Active Ingredients:

Nilotinib
Brand Manufacturer:

Novartis
Manufacturer Location:
Click here to view Product Insert
Click here to view Product Insert
Click here to view Product Insert

Tasigna ^*

For visual reference only; actual product may vary

Prescription Required

All third-party products, company names, and logos are trademarks™ or registered® trademarks are and remain the property of their respective holders. Their use does not imply any affiliation with or endorsement by them. All references on this site to third-party trademarks are intended to constitute nominative fair use under applicable trademark laws.

Tasigna is a targeted anticancer medicine indicated for the treatment of Philadelphia chromosome–positive chronic myeloid leukaemia.

Place your order

Tasigna Brand	200mg 120 Capsules	- Tasigna – Brand, Tasigna, 200mg, 120, Capsules, 37070, Novartis, 2742 + 0	Our price: $4,600.00
Tasigna Brand	150mg 112 Capsules	- Tasigna – Brand, Tasigna, 150mg, 112, Capsules, 3416, Novartis, 2741 + 0	Our price: $3,200.00

*Please note all prices are in US dollars

Description
Side Effects
Indications
FAQ
Video

Tasigna (generic name: nilotinib) is a targeted anticancer medicine indicated for the treatment of Philadelphia chromosome–positive chronic myeloid leukaemia (Ph+ CML). It is a tyrosine kinase inhibitor that selectively inhibits the abnormal BCR-ABL1 kinase produced by the Philadelphia chromosome, a genetic rearrangement that drives uncontrolled production of white blood cells. By blocking this signalling pathway, nilotinib reduces the proliferation of malignant cells and helps the bone marrow return to making healthy blood cells, which can lead to long-lasting improvements that show up clearly in blood tests and genetic checks for patients who are good candidates for this treatment. Tasigna is used in newly diagnosed Ph+ CML and in patients who are no longer benefiting from previous treatment, including by Gleevec (iminatib) or who experienced serious intolerance to prior therapy. Treatment is long-term and requires regular monitoring of blood counts, liver and pancreas function, electrolytes (e.g., potassium and magnesium), and the heart’s electrical activity via ECG.

Dosage

The recommended adult dose depends on treatment setting. For newly diagnosed Ph+ CML, the dose is 600 mg per day given as two 150 mg hard capsules twice daily (approximately every 12 hours). For patients no longer benefiting from previous treatment, the recommended dose is 800 mg per day given as two 200 mg hard capsules twice daily. Paediatric dosing is based on body size; the prescriber calculates the correct dose, not to exceed a total daily dose of 800 mg. Capsules must be taken at least two hours after any food and followed by a one-hour fast before eating again, unless specified differently by the prescribing doctor. Swallow capsules whole with water; if swallowing is not possible, each capsule may be opened and the content mixed with one teaspoon of applesauce and taken immediately (do not use any other food and do not exceed one teaspoon per capsule). Grapefruit products must be avoided. If a dose is missed, the next scheduled dose is taken when due. Do not double-dose to make up for any missed doses.. Treatment is continuous and long-term; any interruption or discontinuation is guided by the prescriber with regular monitoring of blood counts, organ function, electrolytes, and ECG.

Storage

Store below 82 °F/30 °C in the original package to protect the capsules from moisture. Keep out of the sight and reach of children. Do not use after the expiry date shown on the carton and blister (the date refers to the last day of that month). Do not use if the pack is damaged or shows signs of tampering. If in any doubt, consult our blog on safe medicine management.

This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.

The information leaflet that comes with the medication includes full details about possible side effects. Be sure to read and understand these, and if there are any questions, discuss them with a healthcare provider before starting treatment.

Caution

If a sudden allergic reaction (anaphylaxis) occurs shortly after taking Tasigna, with symptoms such as swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, wheezing, rash, hives, blistering, or peeling of the skin, seek emergency medical help immediately.

Pregnancy/breastfeeding
Tasigna may harm an unborn child and is not recommended during pregnancy unless clearly necessary. Effective contraception should be used during treatment and for two weeks after the last dose. Because nilotinib may pass into breast milk, breastfeeding should be avoided during treatment and for two weeks after stopping the medicine.

Tasigna can cause a wide range of side effects. These may affect different body systems, ranging from mild symptoms to serious or life-threatening conditions. They are grouped by how frequently they occur in patients.

Very common side effects may occur in more than one in ten people, including:

Diarrhoea, nausea, constipation, vomiting, abdominal discomfort
Headache, fatigue, lack of energy, night sweats, pain in limbs, bone or spinal pain after discontinuation
Itching, rash, hair loss
Muscle pain
Upper respiratory tract infections (sore throat, runny/stuffy nose, sneezing)
Slowing of growth in children and adolescents

Common side effects that may affect up to one in ten people are:

Pneumonia, bronchitis, ear infections, flu-like illness, sore throat, thrush (oral/vaginal)
Abdominal pain, bloating, flatulence, haemorrhoids, mouth sores (stomatitis)
Bone pain, muscle spasms, joint stiffness, pain (including neck pain)
Acne, dry skin, decreased sensitivity, itching at hair follicles
Insomnia, depression, anxiety, night sweats, tinnitus, headaches
High blood pressure, flushing, leg pain, lower limb ulcers or colour change
Nosebleeds
Heavy periods, erectile dysfunction

Serious risks and medical emergencies

Tasigna may cause severe cardiovascular events, including heart attack, stroke, peripheral arterial disease, blood clots, pancreatitis, hepatitis, liver failure, kidney dysfunction, pulmonary complications, serious infections including reactivation of hepatitis B, and rare but life-threatening skin reactions such as Stevens–Johnson syndrome and toxic epidermal necrolysis. Nervous system disorders including seizures, paralysis, sudden vision changes, and loss of consciousness have also been reported.

Reminder
Not all side effects are listed here. Contact a healthcare provider immediately if unusual or severe symptoms appear. Seek urgent medical attention for chest pain, sudden shortness of breath, neurological changes, severe abdominal pain, jaundice, or signs of allergic reaction.

Ph-positive chronic myeloid leukaemia (CML) is a blood cancer characterized by overproduction of abnormal white blood cells.

Symptoms can include:

persistent fatigue
unexplained weight changes
bone pain
night sweats
early satiety from splenomegaly
recurrent infections
easy bruising or bleeding
anaemia-related shortness of breath.

Some individuals are asymptomatic and diagnosed via abnormal blood counts.

Dosing follows strict fasting rules to prevent excessive exposure. Capsules are taken twice daily, at least two hours after any food, then a one-hour wait precedes the next meal. Capsules are swallowed whole with water; if swallowing is not feasible, each capsule can be opened and mixed with one teaspoon of applesauce and taken immediately. Grapefruit juice and grapefruit should be avoided because they may increase nilotinib levels. Adhering to the fasting window and avoiding interacting foods helps maintain predictable drug levels and reduce adverse effects.
Regular monitoring includes complete blood counts to assess marrow response and tolerability; liver and pancreas function tests; electrolyte checks for potassium and magnesium; and ECGs to evaluate the QT interval. Clinicians additionally monitor cardiovascular risk and watch for signs of fluid retention, pancreatitis, or serious skin reactions. In paediatric patients, growth is followed at regular visits. Monitoring cadence and any dose adjustments are individualized according to response, tolerability, and concomitant medications that might interact with nilotinib.
Nilotinib binds to the ATP-binding site of the BCR-ABL1 tyrosine kinase created by the Philadelphia chromosome translocation. This prevents phosphorylation events needed for proliferation and survival of CML cells, thereby reducing leukemic burden and allowing normal haematopoiesis to recover. Because the kinase is the key driver of disease biology, sustained inhibition can translate into cytogenetic and molecular responses when therapy is taken as directed and monitored appropriately.
CML may be asymptomatic at diagnosis, discovered through routine blood tests showing elevated white counts. When present, symptoms can include fatigue, night sweats, bone or limb pain, abdominal fullness from splenomegaly, recurrent infections, easy bruising or bleeding, and breathlessness related to anaemia. Such manifestations reflect overproduction of abnormal white blood cells and marrow dysfunction. Diagnosis integrates blood counts, bone-marrow/ cytogenetic testing, and molecular assays confirming BCR-ABL1. Targeted therapy such as nilotinib addresses this driver lesion to control disease activity.
Nilotinib can prolong the QT interval, a measure of cardiac repolarization. Prolongation may predispose to arrhythmias, especially in the presence of electrolyte abnormalities, pre-existing heart disease, or interacting medicines. The patient leaflet specifies ECG assessment before starting therapy and at intervals thereafter, with correction of low potassium or magnesium and consideration of cardiovascular risk. Monitoring supports safe dosing and early identification of individuals who may require adjustments or additional investigation.
If a dose is forgotten, the next dose is taken as scheduled without doubling, according to the leaflet’s guidance. Consistent timing of approximately twelve hours between dosessupports steady exposure. Because food substantially increases nilotinib absorption, maintaining the two-hour pre-dose fast and one-hour post-dose fast is emphasized at each administration. Any decisions regarding interruptions, re-starts, or discontinuation are made by the prescribing team based on response, tolerability, and monitoring results.

Getting started with IsraelPharm

Required

Send Your Prescription

Secure Payment

No Hidden Fees

Fast Shipping

Generally 7-10 Business Days

Ordering is
simple and safe.

IsraelPharm has been delivering lost cost prescriptions from Israel for over 15 years worldwide. Daily flights allow us to get your medications dispatched fast! Delivery to the USA is under 10 days and you can track and trace every order.

Categories

Resources